We are live on ! Find out more
KCM

Knoll Capital Management Portfolio holdings

AUM $180M
1-Year Est. Return 66.11%
This Fund
S&P 500
This Quarter Est. Return
-10.57%
1 Year Est. Return
+66.11%
3 Year Est. Return
+268.55%
5 Year Est. Return
+741%
10 Year Est. Return
+10,877.35%
AUM
$109M
AUM Growth
-$12.9M
Cap. Flow
+$5.69M
Cap. Flow %
5.21%
Top 10 Hldgs %
87.05%
Holding
23
New
1
Increased
3
Reduced
4
Closed
–

Top Buys

Rank Stock Value
1
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$4.55M
2
LUMN icon
Lumen
LUMN
+$2.61M
3
OTRK
Ontrak
OTRK
+$477K
4
ALDX icon
Aldeyra Therapeutics
ALDX
+$11.7K

Top Sells

Rank Stock Value
1
KRYS icon
Krystal Biotech
KRYS
+$1.2M
2
ECOR icon
electroCore
ECOR
+$373K
3
GLMD icon
Galmed Pharmaceuticals
GLMD
+$337K
4
SNGX icon
Soligenix
SNGX
+$51.4K

Sector Composition

Rank Sector Weight
1 Healthcare 80.62%
2 Financials 6.84%
3 Materials 4.04%
4 Consumer Staples 3.37%
5 Communication Services 2.51%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BHVN
1
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$35.8M 32.74%
857,494
+107,679
+14% +$4.55M
CRBP icon
2
Corbus Pharmaceuticals
CRBP
$170M
$24.3M 22.22%
166,196
– –
BX icon
3
Blackstone
BX
$104B
$7.47M 6.84%
153,000
– –
ABEO icon
4
Abeona Therapeutics
ABEO
$345M
$5.33M 4.88%
94,391
– –
APLT
5
DELISTED
Applied Therapeutics
APLT
$5.13M 4.7%
467,071
– –
KRYS icon
6
Krystal Biotech
KRYS
$9.88B
$4.17M 3.82%
120,212
-26,878
-18% -$1.2M
MO icon
7
Altria Group
MO
$122B
$3.68M 3.37%
90,000
– –
EIGR
8
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$3.59M 3.29%
11,675
– –
KBA icon
9
KraneShares Bosera MSCI China A 50 Connect Index ETF
KBA
$150M
$2.87M 2.63%
96,000
– –
ALDX icon
10
Aldeyra Therapeutics
ALDX
$91.7M
$2.8M 2.56%
531,568
+2,178
+0.4% +$11.7K
LUMN icon
11
Lumen
LUMN
$6.53B
$2.75M 2.51%
+220,000
New +$2.61M
AVXL icon
12
Anavex Life Sciences
AVXL
$222M
$2.29M 2.09%
724,205
– –
DD icon
13
DuPont de Nemours
DD
$18.6B
$2.14M 1.96%
23,900
– –
DOW icon
14
Dow Inc
DOW
$21.6B
$1.43M 1.31%
30,000
– –
ENTX icon
15
Entera Bio
ENTX
$101M
$1.18M 1.08%
475,540
– –
CTVA icon
16
Corteva
CTVA
$59.7B
$840K 0.77%
30,000
– –
MTEM
17
DELISTED
Molecular Templates, Inc.
MTEM
$751K 0.69%
7,594
– –
SNGX icon
18
Soligenix
SNGX
$5.5M
$748K 0.68%
3,286
-208
-6% -$51.4K
GLMD icon
19
Galmed Pharmaceuticals
GLMD
$3.94M
$696K 0.64%
809
-336
-29% -$337K
OTRK
20
DELISTED
Ontrak
OTRK
$678K 0.62%
478
+316
+195% +$477K
ECOR icon
21
electroCore
ECOR
$51.4M
$481K 0.44%
14,671
-11,810
-45% -$373K
LPCN icon
22
Lipocine
LPCN
$17.1M
$141K 0.13%
2,941
– –
NTBL
23
DELISTED
Notable Labs, Ltd. Ordinary Shares
NTBL
$29K 0.03%
611
– –

Similar funds

MGWA
Monument Group Wealth Advisors Concord, Massachusetts $180M AUM 19.81% 1-Year Est. Return
AW
Alchemi Wealth Essex, Connecticut $180M AUM
FBC
Fairfield, Bush & Co Darien, Connecticut $180M AUM 39.51% 1-Year Est. Return
AIC
Aurora Investment Counsel Atlanta, Georgia $180M AUM 0.3% 1-Year Est. Return
AG
Amiral Gestion Paris, France $180M AUM 9.43% 1-Year Est. Return
PCA
Prospect Capital Advisors Sausalito, California $180M AUM 60.99% 1-Year Est. Return
HIC
Hamrick Investment Counsel Seattle, Washington $180M AUM
FFA
Frazier Financial Advisors Columbus, Ohio $181M AUM 11.16% 1-Year Est. Return

Knoll Capital Management's Q3 2019 Portfolio in Review

As of Q3 2019, Knoll Capital Management held 23 positions worth $109M, down 11% from $122M the previous quarter. Its ten largest holdings account for 87% of the portfolio.

Knoll Capital Management deployed $5.69M of net new capital in Q3 2019, opening 1 new position and adding to 3 existing holdings. Its largest new stake was Lumen: 220,000 shares worth $2.75M.

By sector, the portfolio is most concentrated in Healthcare at 81% of assets, down from 85% a quarter earlier, followed by Financials and Materials.

On the sell side, the largest reduction was Krystal Biotech, an estimated $1.2M trimmed.

  • Knoll Capital Management's largest Q3 2019 buy was Lumen: 220,000 shares worth $2.75M.
  • Knoll Capital Management added most to Biohaven Pharmaceutical Holding Company Ltd. in Q3 2019, an estimated $4.55M increase.
  • Knoll Capital Management's biggest Q3 2019 reduction was Krystal Biotech, cutting an estimated $1.2M.
  • Knoll Capital Management's ten largest holdings make up 87% of its $109M portfolio in Q3 2019.
  • Knoll Capital Management opened 1 new position and closed 0 in Q3 2019.
  • Knoll Capital Management's portfolio value fell 11% quarter-over-quarter to $109M.

Based on Knoll Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.